Rajan Patel

HealthTech Capital is a group of private investors dedicated to funding and mentoring new “HealthTech” start ups at the intersection of healthcare and the computer/consumer electronic world. Our goal is to invest and mentor capital efficient companies that use new scalable business model to improve the efficiency of healthcare delivery from the hospital to the home. HealthTech is now an exploding healthcare market that leverages information technologies to decrease healthcare cost. Historically, venture funding has focused on “Efficacy” (therapeutics drugs and medical devices) and paid little attention to improving “Efficiencies” of healthcare delivery. Today, new paradigm shifting companies like Google, Microsoft, Intel, Apple, Amazon and others are turning their attention to HealthTech. HealthTech supports patient-centric healthcare and is distinct from Healthcare IT, enterprise backbone legacy information systems that are well served by existing major players. Our goal is to invest in capital efficient companies that use new business models to improve the efficiency of healthcare delivery.

Kallisio is revolutionizing cancer care with innovative medtech solutions that empower oncologists to manage treatment-related toxicity and safeguard patients throughout their cancer journey. By developing advanced technologies customized to each patient’s unique anatomy and treatment needs, Kallisio ensures precise therapy delivery while protecting healthy tissues across multiple treatment modalities. The stentra™ oral stent, a 3D-printed, patient-specific device, exemplifies this approach. It provides unparalleled protection for Organs-at-Risk (OARs) during cancer therapy, significantly reducing side effects like oral mucositis. This results in better patient outcomes, enhanced comfort, and improved quality of life during treatment. Through its commitment to precision, innovation, and patient-centered care, Kallisio transforms oncology treatment, enabling clinicians to deliver safer, more effective therapies while reducing the burden of cancer toxicity.

Life Science Angels (LSA) is the premier angel investing organization in the US, focused on investing exclusively in the life sciences. Since 2005, LSA has invested in 100+ companies in medical technology and biotechnology investment opportunities.

Kyto Technology and Life Science, Inc., formerly Kyto Biopharma, Inc., seeks to develop a specialized vehicle for early stage technology and life science companies. The Company operates as a mentor, advisor, external manager and investor for selected privately held companies in the United States of America, Canada and Israel. The Companys portfolio includes CNote Group, Inc. (CNote), Exodos/Achelios Therapeutics, Inc. (Achelios), Seal Rock Therapeutics, Inc., and Crater, LLC (Crater). CNote provides an alternative savings product that pays up to 35x the interest of a traditional savings account. Crater provides the SurveyBot software program, which enables video chat between a moving companys representative and the customer. Achelios is a specialty pharmaceutical company with primary focus on new therapeutic entity (NTE) development for the treatment of pain and inflammation by delivered medications.

HealthTech Capital is a group of private investors dedicated to funding and mentoring new “HealthTech” start ups at the intersection of healthcare and the computer/consumer electronic world. Our goal is to invest and mentor capital efficient companies that use new scalable business model to improve the efficiency of healthcare delivery from the hospital to the home. HealthTech is now an exploding healthcare market that leverages information technologies to decrease healthcare cost. Historically, venture funding has focused on “Efficacy” (therapeutics drugs and medical devices) and paid little attention to improving “Efficiencies” of healthcare delivery. Today, new paradigm shifting companies like Google, Microsoft, Intel, Apple, Amazon and others are turning their attention to HealthTech. HealthTech supports patient-centric healthcare and is distinct from Healthcare IT, enterprise backbone legacy information systems that are well served by existing major players. Our goal is to invest in capital efficient companies that use new business models to improve the efficiency of healthcare delivery.

Using a proven approach that drops risk to near zero, iO life science helps medical device innovators design and develop products patients love. From your vision to verification and validation, the user requirements-driven process delivers significant value. End-to-end control reduces costly, time-consuming iterations and ensures success. By partnering with iO life science you gain access to the best minds in medical device design, engineering and compliance. Recognized for their award-winning healthcare solutions, the iO life science global affiliates bring to the table decades of experience with Class I, II III medical devices, QMS and ISO regulations. Lean and responsive, iO life science guides innovation without suffocation. The team has collaborated with fortune 500 companies such as Novartis, AbbVie and AstraZeneca, as well as startups like Sana, Aidar and Graftworx, on project phases from prototype development to regulatory clearance. Partner today with iO life science to mitigate your risk, keep costs low and get to market faster.